Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)

v3.22.1
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT) - USD ($)
Total
Entira, Inc
Camelina Company Espana SL
Preferred Stock
Series B Convertible Preferred Stock
Common Stock
Common Stock
Entira, Inc
Common Stock
Camelina Company Espana SL
Additional Paid-In Capital
Additional Paid-In Capital
Entira, Inc
Additional Paid-In Capital
Camelina Company Espana SL
Accumulated Deficit
Non - controlling Interests
Beginning Balance at Dec. 31, 2019 $ (24,078,857)     $ 13 $ 344,029     $ 31,259,365     $ (55,682,264)  
Beginning Balance, Shares at Dec. 31, 2019       13,000 34,402,943              
Share-based compensation from issuance of options and compensation-based warrants 326,486             326,486        
Exercise of stock options 90,796       $ 14,470     76,326        
Exercise of stock options, Shares         1,447,017              
Option grants for investment in subsidiaries 5,477,677             8,777       $ 5,468,900
Net loss (10,550,175)                   (10,550,175)  
Ending Balance at Dec. 31, 2020 (28,734,073)     $ 13 $ 358,499     31,670,954     (66,232,439) 5,468,900
Ending Balance, Shares at Dec. 31, 2020       13,000 35,850,089              
Share-based compensation from issuance of options and compensation-based warrants 691,821             691,821        
Shares issued to employees 768,368       $ 1,392     766,976        
Shares issued to employees, Shares         139,164              
Exercise of stock options 12,005       $ 1,125     10,880        
Exercise of stock options, Shares         112,432              
Shares issued upon reverse split to avoid fractional shares         $ 19     (19)        
Shares issued upon reverse split to avoid fractional shares, Shares         1,793              
Conversion of note payable to shares 476,036       $ 15,868     460,168        
Conversion of note payable to shares, Shares         1,586,786              
Purchase of Agribody Technologies, Inc $ 5,000,000 $ 2,463,307 $ 6,712,462   $ 8,305 $ 4,071 $ 13,540 4,991,695 $ 2,459,236 $ 6,698,922    
Purchase of Agribody Technologies, Inc, Shares 830,526   1,353,951   830,526 407,150 1,353,951          
Conversion of Series B Preferred to Common, Shares       (13,000) 1,181,819              
Conversion of Series B Preferred to Common       $ (13) $ 11,818     (11,805)        
Conversion of convertible notes, Shares         53,723              
Conversion of convertible notes $ 308,889       $ 537     308,352        
Issuance of common stock for cash 3,100,000       $ 4,960     3,095,040        
Issuance of common stock for cash, Shares         496,000              
Net loss (51,415,508)                   (51,415,508)  
Ending Balance at Dec. 31, 2021 $ (60,616,693)       $ 420,134     $ 51,142,220     $ (117,647,947) $ 5,468,900
Ending Balance, Shares at Dec. 31, 2021         42,013,433